Hayat Pharmaceutical Industries Co. PLC (ASE:HPIC)

ASE:HPIC Income Statement

Financials in millions JOD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	17.11	16.71	15.81	17.11	16.58
Revenue Growth (YoY)	2.39%	5.72%	-7.61%	3.15%	0.02%
Cost of Revenue	7.02	7.45	5.93	6.01	5.39
Gross Profit	10.09	9.26	9.88	11.09	11.19
Selling, General & Admin	2.15	5.22	6.36	6.45	6.21
Research & Development	-	0.7	0.66	0.58	0.47
Other Operating Expenses	5.47	-0.35	0.02	-0.14	-0.05
Operating Expenses	7.62	5.57	7.04	6.89	6.77
Operating Income	2.47	3.69	2.84	4.2	4.42
Interest Expense	-0.14	-0.15	-0.1	-0.07	-0.09
Other Non Operating Income (Expenses)	0.57	-	-	-	-
EBT Excluding Unusual Items	2.9	3.54	2.74	4.14	4.33
Pretax Income	2.9	3.54	2.74	4.14	4.33
Income Tax Expense	0.51	0.45	0.41	0.61	0.69
Net Income	2.39	3.09	2.33	3.53	3.64
Net Income to Common	2.39	3.09	2.33	3.53	3.64
Net Income Growth	-22.58%	32.73%	-34.04%	-3.12%	3.75%
Shares Outstanding (Basic)	10	10	10	10	10
Shares Outstanding (Diluted)	10	10	10	10	10
EPS (Basic)	0.25	0.33	0.25	0.37	0.38
EPS (Diluted)	0.25	0.33	0.25	0.37	0.38
EPS Growth	-22.58%	32.73%	-34.04%	-3.12%	3.75%
Free Cash Flow	-	1.59	2.44	2.23	3.95
Free Cash Flow Per Share	-	0.17	0.26	0.23	0.42
Dividend Per Share	-	0.220	0.165	0.250	0.250
Dividend Growth	-	33.33%	-34.00%	-	25.00%
Gross Margin	58.98%	55.40%	62.51%	64.85%	67.48%
Operating Margin	14.44%	22.09%	17.96%	24.58%	26.66%
Profit Margin	13.98%	18.49%	14.73%	20.63%	21.96%
Free Cash Flow Margin	-	9.50%	15.45%	13.07%	23.80%
EBITDA	3.73	4.79	3.93	5.26	5.32
EBITDA Margin	21.80%	28.70%	24.84%	30.73%	32.09%
D&A For EBITDA	1.26	1.1	1.09	1.05	0.9
EBIT	2.47	3.69	2.84	4.2	4.42
EBIT Margin	14.44%	22.09%	17.96%	24.58%	26.66%
Effective Tax Rate	17.50%	12.67%	15.07%	14.68%	15.91%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.